There is hope for treatment of HFpEFNov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - UMC Groningen, The Netherlands & Singapore
Professor Lam lists five mechanisms in which she recognizes targets for treatment of patients with heart failure with preserved ejection fraction. These mechanisms are currently tested as therapeutic strategies.
Video navigation menu
- There is currently no treatment for HFpEF that reduces morbidity and mortality 0:18
- Three hemodynamic mechanisms as therapeutic target: LV diastolic dysfunction and left atrial hypertension, pulmonary hypertension and plasma volume overload 0:59
- Two molecular mechanisms: microvascular endothelial dysfunction & inflammation, and changes in fibrose and titin 3:00
This 3-minute education provides a summary of just presented scientific data, recorded during the Dutch WCN congress. The objective is to provide a brief commentary and potential implications of these findings.
Prof. Lam works as a cardiologist at the UMC Groningen, The Netherlands. Dr Carolyn Lam is a Senior Consultant of the National Heart Centre, Singapore and Professor of Duke-NUS Cardiovascular Academic Clinical Program. Dr Lam’s clinical sub-specialty is heart failure, and she is recognized globally for her expertise in heart failure with preserved ejection fraction. She also has expertise in women’s cardiovascular disease, hemodynamics, echocardiography, biomarkers and clinical trials.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.